CN1422160A - 鼻内降钙素制剂 - Google Patents
鼻内降钙素制剂 Download PDFInfo
- Publication number
- CN1422160A CN1422160A CN01807605A CN01807605A CN1422160A CN 1422160 A CN1422160 A CN 1422160A CN 01807605 A CN01807605 A CN 01807605A CN 01807605 A CN01807605 A CN 01807605A CN 1422160 A CN1422160 A CN 1422160A
- Authority
- CN
- China
- Prior art keywords
- composition
- calcitonin
- liquid medicine
- administration
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Abstract
Description
柠檬酸(pH3.7)mM | 生物利用度(%±sdev) | 最大血浆sCT(ng/ml±sdev) |
0 | 0.89±0.19 | 1.10±0.52 |
10 | 3.14±1.77 | 3.66±1.67 |
25 | 5.01±2.34 | 5.11±2.09 |
50 | 6.15±1.31 | 6.05±1.30 |
100 | 13.36±3.38 | 12.98±3.96 |
防腐剂 | 生物利用度(%±sdev) | 最大血浆sCT(ng/ml±sdev) |
无 | 1.14±0.87 | 1.24±0.79 |
0.2%苯乙醇-0.5%苄醇 | 0.89±0.19 | 1.10±0.52 |
0.27%对羟基苯甲酸甲酯-0.04%对羟基苯甲酸丙酯 | 1.08±0.86 | 1.47±1.46 |
%sCT回收 | |||||
柠檬酸(pH3.7) | 0mM | 10mM | 20mM | 50mM | 100mM |
50℃下的天数 | |||||
0 | 100 | 100 | 100 | 100 | 100 |
3 | 83 | 94 | 91 | 90 | 87 |
6 | 53 | 90 | 87 | 83 | 77 |
9 | 24 | 82 | 78 | 73 | 66 |
15 | 22 | 74 | 68 | 61 | 20 |
Claims (23)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18024100P | 2000-02-04 | 2000-02-04 | |
US60/180,241 | 2000-02-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1422160A true CN1422160A (zh) | 2003-06-04 |
CN1183965C CN1183965C (zh) | 2005-01-12 |
Family
ID=22659737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB01807605XA Expired - Fee Related CN1183965C (zh) | 2000-02-04 | 2001-01-31 | 鼻内降钙素制剂 |
Country Status (6)
Country | Link |
---|---|
US (3) | US6440392B1 (zh) |
EP (1) | EP1251867A4 (zh) |
CN (1) | CN1183965C (zh) |
AU (1) | AU783952B2 (zh) |
CA (1) | CA2399505C (zh) |
WO (1) | WO2001056594A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058289A1 (fr) * | 2003-12-16 | 2005-06-30 | Fang Jin | Technique de preparation de produit d'hinalation en poudres deshydratees intranasale de calcitonine |
CN101549149B (zh) * | 2008-09-17 | 2011-12-28 | 北京双鹭药业股份有限公司 | 一种新的降钙素的水溶液鼻用喷雾制剂 |
CN108969754A (zh) * | 2018-09-04 | 2018-12-11 | 深圳大佛药业股份有限公司 | 一种鲑降钙素鼻喷雾剂及其制备方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1251867A4 (en) | 2000-02-04 | 2004-12-08 | Unigene Lab Inc | NASAL CALCITON INFORMATION |
US20090035260A1 (en) * | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
EP1631308B1 (en) * | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
ITMI20040235A1 (it) * | 2004-02-13 | 2004-05-13 | Therapicon Srl | Preparazione farmaceutica per il cavo orale |
US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
US20100256060A1 (en) * | 2009-04-02 | 2010-10-07 | Unigene Laboratories Inc. | Peptide pharmaceuticals for nasal delivery |
US9457086B2 (en) | 2013-03-05 | 2016-10-04 | Enteris Biopharma, Inc. | Pharmaceuticals for oral delivery |
KR102294577B1 (ko) | 2015-01-12 | 2021-08-26 | 엔터리스 바이오파마, 인크. | 고체 경구 제형 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4151276A (en) | 1975-05-12 | 1979-04-24 | Armour Pharmaceutical Company | Method of suppressing gastric acid secretion by the oral administration of calcitonin |
JPS5885813A (ja) | 1981-11-17 | 1983-05-23 | Toyo Jozo Co Ltd | 吸収性良好な製剤 |
US4900730A (en) | 1981-01-14 | 1990-02-13 | Toyo Jozo Co., Ltd. | Preparation which promotes the absorption of peptides |
GB2092002B (en) * | 1981-01-14 | 1985-09-11 | Toyo Jozo Kk | Suppositories injectable solutions |
US5169849A (en) | 1982-02-01 | 1992-12-08 | Sandoz Ltd. | Nasal pharmaceutical compositions |
CH657779A5 (de) | 1982-10-05 | 1986-09-30 | Sandoz Ag | Galenische zusammensetzungen enthaltend calcitonin. |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
AU572815B2 (en) | 1982-12-29 | 1988-05-19 | Armour Pharmaceutical Company | Pharmaceutical calcitonin compositions for intranasal application |
CH657858A5 (de) | 1983-06-27 | 1986-09-30 | Ciba Geigy Ag | Substanz aus der gruppe der calcitonine. |
JPS61267528A (ja) | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
IT1204400B (it) | 1986-06-20 | 1989-03-01 | Sclavo Spa | Composizioni farmaceutiche contenente una calcitonina |
US5938654A (en) | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
DE3887494T2 (de) | 1987-11-13 | 1994-05-19 | Smithkline Beecham Farma | Ein Calcitonin sowie ein Glycyrrhizinat als Absorptionsförderer enthaltende Arzneimittel. |
US5026825A (en) | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
US5514365A (en) | 1988-10-11 | 1996-05-07 | Schiapparelli Salute S.P.A. | Pharmaceutical compositions comprising calcitonin for intranasal administration |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
IT1231957B (it) | 1989-09-15 | 1992-01-16 | Esseti Chimico Farmaco Bio | Composizioni farmaceutiche stabili a base di calcitonina. |
DE69001991T2 (de) | 1989-11-16 | 1993-09-23 | Phidea Spa | Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten. |
US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
GB9007052D0 (en) * | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
JP3219096B2 (ja) | 1990-05-10 | 2001-10-15 | ニコメド ファーマ エイエス | n―グリコフロール類及びn―エチレングリコール類を含有する医薬製剤 |
US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
JPH078806B2 (ja) | 1990-08-16 | 1995-02-01 | 旭化成工業株式会社 | カルシトニン類含有経鼻投与用乳剤 |
IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
EP0489217A1 (en) | 1990-12-05 | 1992-06-10 | Dr. A. Tosi Farmaceutici S.R.L. | Calcitonin compositions for intranasal administration |
US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
IT1254707B (it) | 1991-02-19 | 1995-10-09 | Mediator Srl | Uso topico della calcitonima per la preparazione di medicamenti nella cataratta idiopatica senile e una composizione farmaceutica che la contiene |
GB9108634D0 (en) | 1991-04-23 | 1991-06-12 | Ciba Geigy | Pharmaceutical compositions |
JP3608802B2 (ja) * | 1991-09-20 | 2005-01-12 | 第一サントリーファーマ株式会社 | 安定なカルシトニン医薬組成物及びその製造法 |
US5571788A (en) | 1991-12-09 | 1996-11-05 | Ciba-Geigy Corporation | Stable calcitonin pharmaceutical compositions |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US5654000A (en) | 1992-07-28 | 1997-08-05 | Poli Industria Chimica S.P.A. | Pharmaceutical compositions for transmucosal delivery of peptides |
US5759566A (en) | 1992-07-28 | 1998-06-02 | Poli Industria Chimica Spa | Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents |
FR2697022B1 (fr) | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
IT1255895B (it) | 1992-10-20 | 1995-11-17 | Laura Chiodini | Composizioni farmaceutiche contenenti una calcitonina |
JP3628713B2 (ja) | 1993-06-07 | 2005-03-16 | 帝國製薬株式会社 | 生理学的に活性なペプチドを含有する膣投与製剤 |
SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
KR950007873A (ko) | 1993-09-20 | 1995-04-15 | 후꾸하라 요시하루 | 생리 활성 물질 지속 방출형의 의약 제제 |
US5496801A (en) | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
EP0803255A4 (en) | 1994-06-03 | 1999-06-30 | Tsumura & Co | DRUG |
US5670163A (en) | 1994-06-20 | 1997-09-23 | Kv Pharmaceuticals Company | Long acting GI and esophageal protectant |
DE726075T1 (de) * | 1995-02-08 | 1996-12-12 | Therapicon Srl | Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US5726154A (en) | 1996-06-28 | 1998-03-10 | University Of Utah Research Foundation | Stabilization and oral delivery of calcitonin |
US6440446B1 (en) | 1998-04-22 | 2002-08-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent for anti-osteoporosis |
US6153582A (en) | 1998-11-05 | 2000-11-28 | Bausch & Lomb Surgical, Inc. | Defined serumfree medical solution for ophthalmology |
US6149893A (en) * | 1999-03-01 | 2000-11-21 | Alfa Wassermann S.P.A. | Pharmaceutical compositions containing calcitonin in a spray dosing feeder for intranasal administration |
EP1251867A4 (en) | 2000-02-04 | 2004-12-08 | Unigene Lab Inc | NASAL CALCITON INFORMATION |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
-
2001
- 2001-01-31 EP EP01908769A patent/EP1251867A4/en not_active Withdrawn
- 2001-01-31 WO PCT/US2001/003212 patent/WO2001056594A1/en active IP Right Grant
- 2001-01-31 CN CNB01807605XA patent/CN1183965C/zh not_active Expired - Fee Related
- 2001-01-31 CA CA2399505A patent/CA2399505C/en not_active Expired - Fee Related
- 2001-01-31 AU AU36604/01A patent/AU783952B2/en not_active Ceased
- 2001-02-02 US US09/776,537 patent/US6440392B1/en not_active Ceased
-
2004
- 2004-02-05 US US10/774,358 patent/USRE40812E1/en not_active Expired - Lifetime
-
2009
- 2009-06-29 US US12/459,385 patent/USRE43580E1/en not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005058289A1 (fr) * | 2003-12-16 | 2005-06-30 | Fang Jin | Technique de preparation de produit d'hinalation en poudres deshydratees intranasale de calcitonine |
CN101549149B (zh) * | 2008-09-17 | 2011-12-28 | 北京双鹭药业股份有限公司 | 一种新的降钙素的水溶液鼻用喷雾制剂 |
CN108969754A (zh) * | 2018-09-04 | 2018-12-11 | 深圳大佛药业股份有限公司 | 一种鲑降钙素鼻喷雾剂及其制备方法 |
CN108969754B (zh) * | 2018-09-04 | 2019-06-21 | 深圳大佛药业股份有限公司 | 一种鲑降钙素鼻喷雾剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2399505A1 (en) | 2001-08-09 |
WO2001056594A1 (en) | 2001-08-09 |
US6440392B1 (en) | 2002-08-27 |
USRE43580E1 (en) | 2012-08-14 |
AU3660401A (en) | 2001-08-14 |
CA2399505C (en) | 2012-01-03 |
USRE40812E1 (en) | 2009-06-30 |
AU783952B2 (en) | 2006-01-05 |
EP1251867A4 (en) | 2004-12-08 |
EP1251867A1 (en) | 2002-10-30 |
CN1183965C (zh) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4690952A (en) | Pharmaceutical compositions for nasal administration comprising calcitonin and an absorption-promoting substance | |
USRE43580E1 (en) | Nasal calcitonin formulations | |
JP4405666B2 (ja) | 安定化テリパラチド溶液剤 | |
EP0999841B1 (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
US7550434B2 (en) | Stabilized teriparatide solutions | |
JP3795520B2 (ja) | 安定化製薬性ペプチド組成 | |
Kobayashi et al. | Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats | |
EP0505123A1 (en) | Pulmonary administration of granulocyte colony stimulating factor | |
EP0566135A1 (en) | Transmucosal composition comprising a peptide and a cytidine derivative | |
US5763398A (en) | Nasal administration of desmopressin | |
WO1990009167A1 (en) | Composition and method for administration of pharmaceutically active substances | |
JPH05508616A (ja) | 治療用エアロゾル剤 | |
JP2009502967A (ja) | 粘膜送達を向上させるためのタイトジャンクション調節ペプチド化合物 | |
JPH07103043B2 (ja) | カルシトニン組成物およびその用途 | |
CN1319003A (zh) | 蛋白质制剂 | |
Harris et al. | Nasal administration of desmopressin by spray and drops | |
KR20120004981A (ko) | 경비 전달용 펩티드 약제 | |
Hanson et al. | Intranasal delivery of the peptide, salmon calcitonin | |
JP2004506678A (ja) | 全身性疾患を治療する方法 | |
CN101549149B (zh) | 一种新的降钙素的水溶液鼻用喷雾制剂 | |
Rogerson et al. | Nasal drug delivery | |
EP1779864A1 (en) | Pth-containing preparation for transmucosal administration | |
AP1100A (en) | Pharaceutical compositions containing eletriptan hemisulphate. | |
JPH07138184A (ja) | エルカトニン水性注射用製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161115 Address after: New jersey, USA Patentee after: Endelisi Biological Pharmaceutical Co.,Ltd. Address before: American New Jersey Patentee before: Unigene Laboratories, Inc. Patentee before: UGP therapeutics Inc. Effective date of registration: 20161115 Address after: Illinois USA Patentee after: UGP therapeutics Inc. Address before: American New Jersey Patentee before: Unigene Laboratories, Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050112 Termination date: 20180131 |
|
CF01 | Termination of patent right due to non-payment of annual fee |